Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes

The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management of type 2 diabetes mellitus (T2DM) by shifting emphasis from a gluco-centric approach to holistically treating underlying pathophysiological processes. DPP-4 inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Strain, William David, Paldánius, Päivi M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2017
Materias:
Type 2 Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813466/
https://www.ncbi.nlm.nih.gov/pubmed/29632609
http://dx.doi.org/10.17925/EE.2017.13.02.62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813466/
https://www.ncbi.nlm.nih.gov/pubmed/29632609
http://dx.doi.org/10.17925/EE.2017.13.02.62

Ejemplares similares